Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Weissman

Dermatology New York, NY Medical Doctor

NPI 1164408282 CMS profile 325065

51 E 125Th Street, 2Nd Floor, New York, NY 10035

Open in the dashboard

General payments

$7,277

375 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Weissman of New York, NY is reported in the CMS Open Payments database as having received $7,277 across 375 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $630 35
2024 General $1,314 77
2023 General $891 42
2022 General $747 31
2021 General $456 23
2020 General $665 35
2019 General $2,574 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Weissman
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Steven Weissman were reported at $630. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Steven Weissman Dermatology median Middle half National median
2019 $2,574 $454 $129–$1,240 $163
2020 $665 $235 $81–$756 $114
2021 $456 $377 $108–$1,108 $132
2022 $747 $514 $143–$1,391 $149
2023 $891 $607 $159–$1,674 $160
2024 $1,314 $751 $204–$1,903 $164
2025 $630 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,800 70 payments
  2. AbbVie, Inc. $648 50 payments
  3. Sun Pharmaceutical Industries Inc. $520 26 payments
  4. Pfizer Inc. $518 38 payments
  5. E.R. Squibb & Sons, L.L.C. $440 35 payments
  6. PruGen, Inc. Pharmaceuticals $407 8 payments
  7. Ortho Dermatologics, a division of Bausch Health US, LLC $394 19 payments
  8. Novartis Pharmaceuticals Corporation $374 21 payments
  9. Dermavant Sciences, Inc. $257 8 payments
  10. Janssen Scientific Affairs, LLC $233 2 payments
  11. Other $1,686 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,819 369 payments
  2. Education $458 6 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $2,009 70 payments
  2. SOTYKTU $440 35 payments
  3. ILUMYA $413 21 payments
  4. EUCRISA $376 30 payments
  5. CIBINQO $304 18 payments
  6. LITFULO $283 17 payments
  7. HUMIRA $271 22 payments
  8. VTAMA $257 8 payments
  9. SKYRIZI $220 15 payments
  10. DUOBRII $216 6 payments
  11. Other $2,539 155 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,260

Median for Dermatology: 534

Drug cost

$606,417

Median for Dermatology: $67,151

Branded share of claims

20.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tremfya Guselkumab Brand 15 $212,208
Taltz Autoinjector Ixekizumab Brand 17 $146,505
Rinvoq Upadacitinib Brand 20 $125,350
Opzelura Ruxolitinib Phosphate Brand 36 $75,711
Tacrolimus Generic 113 $11,089
Eucrisa Crisaborole Brand 11 $8,390
Metronidazole Generic 45 $4,755
Halobetasol Propionate Generic 78 $3,483
Clobetasol Propionate Generic 87 $2,202
Fluorouracil Generic 31 $2,064

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$46,196

Of which drugs: $49

Medicare patients

140

Average age 71

Services billed

591

84 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Diabetes 51%
Arthritis 46%
Ischemic heart disease 29%
Chronic kidney disease 16%
Depression 15%
Heart failure 14%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 28 68 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $440
$440 — —
TREMFYA
  • Janssen Biotech, Inc. $156
$156 15 —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $92
$92 — —
CIBINQO
  • PFIZER INC. $60
$60 — —
LITFULO
  • PFIZER INC. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

375 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record